Loading...
Loading...
XERS| Name | Value |
|---|---|
| Revenues | 54.3M |
| Cost of Revenue | 13.6M |
| Gross Profit | 40.7M |
| Operating Expense | 53.6M |
| Operating I/L | -12.9M |
| Other Income/Expense | -6.2M |
| Interest Income | 1.2M |
| Pretax | -19.1M |
| Income Tax Expense | -3.3M |
| Net Income/Loss | -15.7M |
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company specializing in developing and commercializing therapies for endocrinology, neurology, and gastroenterology patient populations. The company's revenue is generated through the marketing of Gvoke, a liquid glucagon for severe hypoglycemia; Keveyis, a treatment for various forms of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for Cushing's syndrome. Additionally, Xeris Biopharma has a pipeline of development programs aimed at expanding the applications of its existing products and introducing new therapies utilizing its proprietary formulation technology platforms, XeriSol and XeriJect.
